Controlled Trial on the Short-term Effects of Sacubitril/Valsartan Therapy on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Patients With NYHA II-III Heart Failure and Reduced Systolic Function Using 11C-acetate Positron Emission Tomography and Echocardiography
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms TurkuPET
- Sponsors Novartis Pharmaceuticals
- 23 Jul 2018 Planned End Date changed from 31 Aug 2019 to 2 Sep 2019.
- 23 Jul 2018 Planned primary completion date changed from 31 Aug 2019 to 4 Feb 2019.
- 23 Jul 2018 Status changed from not yet recruiting to recruiting.